Contrave: Phase III data

In the double-blind, U.S. Phase III COR-Diabetes (NB-304) trial in 424 evaluable Type II diabetics, Contrave (32 mg naltrexone SR/360 mg bupropion SR) met the co-primary endpoints of the proportion of...